OptimizeRx Corporation 2025-2026 Proxy Voting Records

Description as filed by funds: Election of each of the seven director nominees listed below: Catherine Klema

OptimizeRx Corporation’s own tally for this item (“Elect Director: Catherine Klema”): 9,079,088 for, 3,574,708 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were each elected to serve as director for a term that expires at the next annual meeting of shareholders and until his or her successor has been elected and qualified or until his or her earlier death, resignation or removal based upon the following votes:”
Support: 72% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 2,451,952 for, 368,491 withheld, 12,525 abstained.

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

Description as filed by funds: Election of each of the seven director nominees listed below: Gregory D. Wasson

OptimizeRx Corporation’s own tally for this item (“Elect Director: Gregory Wasson”): 10,324,948 for, 2,328,848 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were each elected to serve as director for a term that expires at the next annual meeting of shareholders and until his or her successor has been elected and qualified or until his or her earlier death, resignation or removal based upon the following votes:”
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 2,598,655 for, 227,901 withheld, 6,412 abstained.

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

Description as filed by funds: Election of each of the seven director nominees listed below: James Lang

OptimizeRx Corporation’s own tally for this item (“Elect Director: James Lang”): 10,329,173 for, 2,324,623 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were each elected to serve as director for a term that expires at the next annual meeting of shareholders and until his or her successor has been elected and qualified or until his or her earlier death, resignation or removal based upon the following votes:”
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 2,591,416 for, 235,140 withheld, 6,412 abstained.

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

Description as filed by funds: Election of each of the seven director nominees listed below: Lynn O'Connor Vos

OptimizeRx Corporation’s own tally for this item (“Elect Director: Lynn O'Connor Vos”): 8,327,850 for, 4,325,946 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were each elected to serve as director for a term that expires at the next annual meeting of shareholders and until his or her successor has been elected and qualified or until his or her earlier death, resignation or removal based upon the following votes:”
Support: 66% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 2,453,748 for, 367,993 withheld, 11,227 abstained.

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

Description as filed by funds: Election of each of the seven director nominees listed below: Mariyamma Varghese Presti

OptimizeRx Corporation’s own tally for this item (“Elect Director: Mariyamma Varghese Presti”): 11,766,568 for, 887,228 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were each elected to serve as director for a term that expires at the next annual meeting of shareholders and until his or her successor has been elected and qualified or until his or her earlier death, resignation or removal based upon the following votes:”
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 2,831,253 for, 1,713 withheld, 2 abstained.

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

Description as filed by funds: Election of each of the seven director nominees listed below: Patrick Spangler

OptimizeRx Corporation’s own tally for this item (“Elect Director: Patrick Spangler”): 8,092,151 for, 4,561,645 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were each elected to serve as director for a term that expires at the next annual meeting of shareholders and until his or her successor has been elected and qualified or until his or her earlier death, resignation or removal based upon the following votes:”
Support: 64% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 2,362,048 for, 459,693 withheld, 11,227 abstained.

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

Description as filed by funds: Election of each of the seven director nominees listed below: Stephen Silvestro

OptimizeRx Corporation’s own tally for this item (“Elect Director: Stephen Silvestro”): 12,160,558 for, 493,238 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The following nominees were each elected to serve as director for a term that expires at the next annual meeting of shareholders and until his or her successor has been elected and qualified or until his or her earlier death, resignation or removal based upon the following votes:”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 2,831,254 for, 1,713 withheld, 1 abstained.

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.

Description as filed by funds: APPROVAL OF AN AMENDMENT TO THE 2021 EQUITY PLAN TO ADOPT AN EVERGREEN PROVISION PROVIDING FOR AN AUTOMATIC ANNUAL INCREASE IN THE SHARES OF COMMON STOCK AVAILABLE FOR ISSUANCE UNDER THE 2021 EQUITY PLAN.

OptimizeRx Corporation’s own tally for this item (“4. The amendment to the Equity Plan to adopt an evergreen provision providing for an automatic annual increase in the shares of Common Stock available for issuance under the Equity Plan”): 5,627,324 for, 7,001,699 against — failed, per its Form 8-K filed June 12, 2026 (Item 5.07).

Reported outcome: Not approved, in the filing’s own words: “The amendment to the Equity Plan to adopt an evergreen provision providing for an automatic annual increase in the shares of Common Stock available for issuance under the Equity Plan was not approved based upon the following votes:”
Support: 45% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 48 asset managers below reported 555,252 for, 2,262,903 against, 1,713 abstained.

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.

Description as filed by funds: Approval of an amendment to the Company's 2021 Equity Incentive Plan (the "2021 Equity Plan") to increase the aggregate number of shares of Common Stock available for awards by 1,000,000 shares to 5,450,000 shares.

OptimizeRx Corporation’s own tally for this item (“3. Amendment to the Equity Plan to increase the aggregate number of shares of Common Stock available for awards under the Equity Plan by 1,000,000 shares”): 11,541,123 for, 1,096,197 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: The amendment to the Equity Plan to increase the aggregate number of shares of Common Stock available for awards under the Equity Plan by 1,000,000 shares was approved based upon the following votes:”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 48 asset managers below reported 2,621,611 for, 196,544 against, 1,713 abstained.

Showing the 25 largest of 48 asset managers. See all 48 in the interactive database.

Description as filed by funds: ADVISORY (NON-BINDING) APPROVAL OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

OptimizeRx Corporation’s own tally for this item (“2. The compensation of the Company's named executive officers, as described in the proxy statement”): 11,660,549 for, 895,095 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The compensation of the Company's named executive officers, as described in the proxy statement, was approved on an advisory basis based upon the following votes:”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of OptimizeRx Corporation’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (3 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 48 managers: 2,614,408 for, 203,747 against, 1,713 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 108 managers: 6,016,540 for, 60,902 against, 77,260 withheld. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Ratification of Grant Thornton LLP as OptimizeRx's independent registered public accounting firm for the fiscal year ending December 31, 2026.

OptimizeRx Corporation’s own tally for this item (“5. Grant Thornton LLP”): 15,750,329 for, 27,585 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Grant Thornton LLP was ratified as the Company's independent registered public accounting firm for the 2026 fiscal year based upon the following votes:”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 49 asset managers below reported 2,831,255 for, 1,713 abstained.

Showing the 25 largest of 49 asset managers. See all 49 in the interactive database.